During the past decade, Denver CyberKnife conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Denver CyberKnife" #1 collaborator was "M.D. Anderson Cancer Center" with 1 trials as a collaborator and "University of Pittsburgh" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Denver CyberKnife" are "Non-small Cell Lung Cancer" (2 trials). Many other conditions were trialed in "Denver CyberKnife" in a lesser frequency.

Most popular intervention types in "Denver CyberKnife" are "Radiation" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "CyberKnife Stereotactic Radiosurgery" (1 trials), "CyberKnife Stereotactic Radiotherapy" (1 trials) and "Surgery" (1 trials). Other intervention names were less common.

The vast majority of trials in "Denver CyberKnife" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Denver CyberKnife". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Denver CyberKnife, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Denver CyberKnife, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".